Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

Authors

  • Chihiro Murano Postgraduate Clinical Training Center, Yamagata University Hospital
  • Akira Igarashi Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan
  • Keiko Yamauchi Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan
  • Sumito Inoue Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan, Tel: +81-23-628-5302; Fax: +81-23-628-5305; E-mail: sinoue@med.id.yamagata-u.ac.jp
  • Masafumi Watanabe Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, Yamagata, Japan

DOI:

https://doi.org/10.17179/excli2019-1786

Keywords:

lung cancer, adenocarcinoma, EGFR exon 20 insertion gene mutation, osimertinib

Abstract

A 20-year-old woman was diagnosed with stage 4 lung adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation. Although the patient underwent chemotherapy, her lesions progressed. Liquid biopsy for EGFR T790M mutation showed negative results. After administering osimertinib, reduction of the lesions at the primary site was observed, and the patient’s respiratory condition improved. Previous reports showing successful treatment of EGFR exon 20 insertion-positive lung adenocarcinoma with the standard osimertinib dose of 80 mg are limited. The present case demonstrated that osimertinib could be a possible treatment option for EGFR exon 20 insertion-positive lung adenocarcinoma.

Downloads

Published

2019-10-07

How to Cite

Murano, C., Igarashi, A., Yamauchi, K., Inoue, S., & Watanabe, M. (2019). Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma. EXCLI Journal, 18, 893–898. https://doi.org/10.17179/excli2019-1786

Issue

Vol. 18 (2019)

Section

Case reports

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)